Of particular importance is that selective CaV1.1, CaV2.1, and CaV2.2 channel blockers substantially improve defects in neuromuscular activity and viability induced by IgGs from ALS patients (2, 18, 20, , –23). The gene discussed is CACNA1S; the disease is amyotrophic lateral sclerosis.